JPRN-UMIN000017894已完成2 期
Phase II study of gemcitabine plus oxaliplatin combination therapy (GEMOX therapy) for the advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or with a personal history of breast/ovarian/prostate cancer. - FABRIC study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 45
研究概览
简要总结
Among the first 43 enrolled patients, the 1-year survival rate was 27.9% (90% CI 17.0-41.3). This trial did not meet its primary endpoint because the lower limit of the 90% CI was lower than the prespecified threshold of 30%.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Synchronous or metachronous (within 3 years) malignancies except carcinoma in situ or intramucosal tumor curatively treated with local therapy 2) Known metastasis to the central nervus system 3) Presence of uncontrollable moderate or severe ascites and/or pleural effusion 4) Grade 2 or more of peripheral sensory neuropathy or peripheral motor neuropathy 5) Oral intake is impossible 6) Major surgery within 4 weeks 7) Blood transfusion or G-CSF within 2 weeks 8) Patients requiring systemic steroids medication 9) Unstable angina pectoris within 3 weeks, or with a history of myocardial infarction within 6 months 10) Interstitial pneumonia, pulmonary fibrosis 11) Severe complications such as heart failure, renal failure, liver failure, peptic ulcer with active bleeding, intestinal paralysis, uncontrolled diabetes mellitus, etc 12) Active infection requiring systemic therapy 13) Pregnant or lactating women or women of childbearing potential, Male expecting partner's pregnancy 14) Psychosis or severe mental disorder 15) History of sever allergic reaction to gemcitabine or oxaliplatin 16) Impossible to use both iodine and gadolinium due to being allergic to contrast agent 17) Inadequate physical condition, as diagnosed by attending physician
研究者
相似试验
进行中（未招募）
1 期
Fase II trial with gemcitabine and oxaliplatin in patients with unknown primary tumours - UPT - unfitTo test the effect of Gemcitabine and axaliplatin in patients with unknown primary tumours and performance 2 or age 66 to 75EUCTR2005-001959-38-DKGedske Daugaard39
终止
2 期
A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast CancerBreast CancerNCT00674206Emory University6
已完成
2 期
Efficacy Study of GEMOX Combination and Vinorelbine in NSCL PatientsNon Small Cell Lung CancerNCT00271271Sanofi40
已完成
2 期
Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the UterusMixed Mullerian Tumors of the UterusNCT00476086Dana-Farber Cancer Institute20
已完成
2 期
Biliary Cancers: EGFR INhibitor, Gemcitabine and OxaliplatinAdvanced Biliary CancerNCT00552149Gustave Roussy, Cancer Campus, Grand Paris150